AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12072848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone motion palpation
Number of subjects: 85
Study 12072848 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal palpation for tenderness
Number of subjects: 85
Study 9925834 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily (QD)
Number of subjects: 480
Study 9925834 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg twice a day (BID)
Number of subjects: 480
Study 9925834 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg BID
Number of subjects: 480
Study 9925834 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg QD
Number of subjects: 480
Study 9925834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 7753566 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed ring apparatus (Ace Medical, Los Angeles, California)
Number of subjects: 24
Study 7753566 — intervention group
Group type: EXPERIMENTAL
Intervention: Open ring device (Bremer, Inc, Jacksonville, Florida)
Number of subjects: 24
Study 2307249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with cryopreserved sperm
Number of subjects: 154
Study 2307249 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination (ICI) with cryopreserved sperm
Number of subjects: 154
Study 656715 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment for three months
Number of subjects: 32
Study 656715 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment for six months
Number of subjects: 32
Study 30791083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental splint (1-2 mm thick)
Number of subjects: 22
Study 30791083 — intervention group
Group type: COMPARATOR
Intervention: No dental splint
Number of subjects: 22
Study 28257617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions of range‐of‐motion exercises plus 6 sessions of stretching and strengthening exercises (exercise group)
Number of subjects: 140
Study 28257617 — intervention group
Group type: COMPARATOR
Intervention: 2 sessions of cervicothoracic manipulation and range‐of‐motion exercises followed by 6 sessions of stretching and strengthening exercise (manipulative‐therapy‐plus‐exercise group)
Number of subjects: 140
Study 25951477 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cleaning with multipurpose disinfection solution (MPDS)
Number of subjects: 193
Study 25951477 — intervention group
Group type: COMPARATOR
Intervention: Control (no daily cleaning)
Number of subjects: 193
Study 23860695 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 80
Study 23860695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 80
Study 23860695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Group D and Group S
Number of subjects: 80
Study 20643989 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one advance planning intervention consisting of counseling and completing an advance directive with a social worker
Number of subjects: 262
Study 20643989 — intervention group
Group type: COMPARATOR
Intervention: Minimal, self-guided intervention consisting of advance directive forms and written educational information
Number of subjects: 262
Study 18327066 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 126137
Study 18327066 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 126137
Study 18327066 — intervention group
Group type: COMPARATOR
Intervention: Beta-adrenergic blockers
Number of subjects: 126137
Study 18327066 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 126137
Study 18327066 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 126137
Study 18327066 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/untreated control
Number of subjects: 126137
Study 15898290 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.12% foam
Number of subjects: 19
Study 15898290 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 19
Study 12828818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus Calculator (Medtronic MiniMed)
Number of subjects: 49
Study 12828818 — intervention group
Group type: COMPARATOR
Intervention: Standard Bolus
Number of subjects: 49
Study 10823362 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 4526
Study 10823362 — intervention group
Group type: COMPARATOR
Intervention: Comparator NSAIDs
Number of subjects: 4526
Study 9340416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with tunnel incision (5 mm, no sutures)
Number of subjects: 92
Study 9340416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with tunnel incision (8 mm, single sutures)
Number of subjects: 92
Study 9340416 — intervention group
Group type: COMPARATOR
Intervention: Control group (scleral flap incision, double continuous sutures)
Number of subjects: 92
Study 2050179 — intervention group
Group type: EXPERIMENTAL
Intervention: Doryx' (100 mg)
Number of subjects: 97
Study 2050179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibramycin' (100 mg)
Number of subjects: 97
Study 2050179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 6134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0
Study 6134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin spray
Number of subjects: 0
Study 6134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release transmucosal nitroglycerin
Number of subjects: 0
Study 6134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate
Number of subjects: 0
Study 6134467 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent nitroglycerin ointment
Number of subjects: 0
Study 6134467 — intervention group
Group type: COMPARATOR
Intervention: Long-acting nitrates
Number of subjects: 0
Study 29436371 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 100
Study 29436371 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 100
Study 26518211 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT (melphalan, prednisone, and thalidomide)
Number of subjects: 82
Study 26518211 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD (cyclophosphamide, thalidomide, and dexamethasone)
Number of subjects: 82
Study 26518211 — intervention group
Group type: EXPERIMENTAL
Intervention: TD (thalidomide and dexamethasone)
Number of subjects: 82
Study 26518211 — intervention group
Group type: COMPARATOR
Intervention: MPT
Number of subjects: 82
Study 26518211 — intervention group
Group type: COMPARATOR
Intervention: CTD
Number of subjects: 82
Study 26518211 — intervention group
Group type: COMPARATOR
Intervention: TD
Number of subjects: 82
Study 24399088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin or Amoxicillin
Number of subjects: 0
Study 24399088 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporin and Macrolide
Number of subjects: 0
Study 23525934 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA (24 μg/kg/h for 96 h)
Number of subjects: 411
Study 23525934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 21537858 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfusosin, 10 mg/24 h for at least 4 weeks
Number of subjects: 20
Study 21537858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field at radiofrequencies, 30 min daily, 5 consecutive days per week for 2 weeks
Number of subjects: 20
Study 21537858 — intervention group
Group type: COMPARATOR
Intervention: Control group (Alfusosin)
Number of subjects: 20
Study 18264697 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg MPH
Number of subjects: 13
Study 18264697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17036477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-salt-partitioned moxibustion at Shenque (CV 8)
Number of subjects: 82
Study 17036477 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 82
Study 12727767 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 236
Study 12727767 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 236
Study 11028700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vestibular labyrinth hypofunction
Number of subjects: 15
Study 11028700 — intervention group
Group type: COMPARATOR
Intervention: Nonimpaired controls
Number of subjects: 15
Study 9463116 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid level in aqueous humor of patients with cataract
Number of subjects: 32
Study 9463116 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 32
Study 9463116 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between cataract patients and control group
Number of subjects: 32
Study 1311351 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate (20 mg of antimony per kilogram per day intravenously for 20 days)
Number of subjects: 120
Study 1311351 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole (600 mg per day orally for 28 days)
Number of subjects: 120
Study 1311351 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 6707244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 9
Study 6707244 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg methylphenidate
Number of subjects: 9
Study 6707244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6707244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 21 mg methylphenidate
Number of subjects: 9
Study 31241173 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (various doses)
Number of subjects: 132
Study 30270576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 37
Study 30270576 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional food meals
Number of subjects: 37
Study 30270576 — intervention group
Group type: COMPARATOR
Intervention: Standard meals
Number of subjects: 37
Study 27076578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 4 weeks
Number of subjects: 34
Study 27076578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 24605819 — intervention group
Group type: EXPERIMENTAL
Intervention: Algal docosahexaenoic acid supplementation (600 mg day(-1) for 16 weeks)
Number of subjects: 395
Study 24605819 — intervention group
Group type: EXPERIMENTAL
Intervention: Algal docosahexaenoic acid supplementation
Number of subjects: 395
Study 24605819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 22828535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with levobupivacaine
Number of subjects: 120
Study 22828535 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol administration per rectally
Number of subjects: 120
Study 20056639 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, tailored computer instruction at baseline and four monthly lay health advisor counseling sessions
Number of subjects: 181
Study 20056639 — intervention group
Group type: COMPARATOR
Intervention: Low-dose comparison group consisting of a culturally appropriate mammography screening pamphlet
Number of subjects: 181
Study 20056639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (computer program + lay health advisor)
Number of subjects: 181
Study 20056639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 181
Study 18019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals with insulin resistance
Number of subjects: 56
Study 18019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese type 2 diabetics treated with metformin
Number of subjects: 56
Study 18019665 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese healthy individuals)
Number of subjects: 56
Study 15668481 — intervention group
Group type: EXPERIMENTAL
Intervention: CCND1 A870G polymorphism (A allele)
Number of subjects: 1126
Study 12973167 — intervention group
Group type: EXPERIMENTAL
Intervention: Social worker intervention for families of patients at high risk for decisional conflict
Number of subjects: 873
Study 10770450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 17
Study 10770450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 17
Study 8681493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazapertine (5 to 50 mg over 7 days; n = 10)
Number of subjects: 13
Study 8681493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazapertine (20 or 30 mg)
Number of subjects: 13
Study 8681493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazapertine (40 mg)
Number of subjects: 13
Study 8681493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazapertine (incremental dosing)
Number of subjects: 13
Study 8681493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 13
Study 1920817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KET) 40 mg
Number of subjects: 20
Study 1920817 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 20
Study 1920817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KET) 40 mg + Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 20
Study 6227244 — intervention group
Group type: EXPERIMENTAL
Intervention: megadose multi-vitamin/mineral supplement for 4 months
Number of subjects: 24
Study 6227244 — intervention group
Group type: COMPARATOR
Intervention: placebo in identical form
Number of subjects: 24
Study 31743334 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-OSP antibody responses
Number of subjects: 0
Study 31743334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibriocidal responses
Number of subjects: 0
Study 31743334 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA anti-OSP in blood group O individuals
Number of subjects: 0
Study 31743334 — intervention group
Group type: COMPARATOR
Intervention: Comparison with endemic zone cohorts
Number of subjects: 0
Study 29272357 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg orally twice daily for 12 weeks
Number of subjects: 15
Study 29272357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 15
Study 26791028 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 60
Study 26791028 — intervention group
Group type: COMPARATOR
Intervention: Nonaugmented repair
Number of subjects: 60
Study 26791028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25491391 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC treatment in combination with everolimus and prednisolone
Number of subjects: 70
Study 25491391 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving everolimus, prednisolone, and standard dose tacrolimus
Number of subjects: 70
Study 22406532 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study 22406532 — intervention group
Group type: COMPARATOR
Intervention: Niacin + PGD₂ receptor DP1 antagonist
Number of subjects: 0
Study 22406532 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma
Number of subjects: 0
Study 22406532 — intervention group
Group type: COMPARATOR
Intervention: COX inhibitors
Number of subjects: 0
Study 22406532 — intervention group
Group type: COMPARATOR
Intervention: Platelet depletion, COX‐1 knockdown, COX‐2 deletion in mice
Number of subjects: 0
Study 21054285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(2) 1,000 IU/d
Number of subjects: 302
Study 21054285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 17985420 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX, sulfasalazine, and prednisone (Group 3)
Number of subjects: 508
Study 17985420 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX and infliximab (Group 4)
Number of subjects: 508
Study 17985420 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy (Group 1)
Number of subjects: 508
Study 17985420 — intervention group
Group type: COMPARATOR
Intervention: Step‐up to combination therapy (Group 2)
Number of subjects: 508
Study 17985420 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 508
Study 16283981 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive radial artery harvesting (LIRAH)
Number of subjects: 177
Study 16283981 — intervention group
Group type: COMPARATOR
Intervention: Conventional radial artery harvesting (CRAH)
Number of subjects: 177
Study 11896097 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hepatic arterial floxuridine combined with intravenous continuous‐infusion fluorouracil (chemotherapy arm)
Number of subjects: 109
Study 11896097 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no further therapy)
Number of subjects: 109
Study 9860205 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm)
Number of subjects: 40
Study 9860205 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilatory support
Number of subjects: 40
Study 7608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemiluminometric assays (ICMA) for LH
Number of subjects: 375
Study 7608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemiluminometric assays (ICMA) for FSH
Number of subjects: 375
Study 7608809 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH stimulation test for LH
Number of subjects: 375
Study 7608809 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH stimulation test for FSH
Number of subjects: 375
Study 7608809 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ICMA with immunofluorometric assay and radioimmunoassay
Number of subjects: 375
Study 7608809 — intervention group
Group type: EXPERIMENTAL
Intervention: ICMA for LH
Number of subjects: 375
Study 2122713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (IL) phospholipid, n = 5
Number of subjects: 11
Study 2122713 — intervention group
Group type: COMPARATOR
Intervention: 20% Intralipid (IL) phospholipid, n = 6
Number of subjects: 11
Study 373908 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus vincristine (AV)
Number of subjects: 110
Study 373908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy radiotherapy (RT)
Number of subjects: 110
Study 373908 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional chemotherapy (6 more cycles)
Number of subjects: 110
Study 373908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment modality
Number of subjects: 110
Study 31095954 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV plus IVB (1.25 mg bevacizumab)
Number of subjects: 224
Study 31095954 — intervention group
Group type: COMPARATOR
Intervention: PPV plus sham
Number of subjects: 224
Study 28114915 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behavior Therapy (TCBT)
Number of subjects: 248
Study 28114915 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis specific group CBT
Number of subjects: 248
Study 25851385 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 155
Study 25851385 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (control)
Number of subjects: 155
Study 22222299 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent potassium calcium citrate (PCC)
Number of subjects: 15
Study 22222299 — intervention group
Group type: COMPARATOR
Intervention: Citracal Petite (tablet formulation of calcium citrate)
Number of subjects: 15
Study 21116175 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 19
Study 21116175 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (Control)
Number of subjects: 19
Study 20214047 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin-like growth factor-1 (IGF-1) level
Number of subjects: 15
Study 16901421 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine or sodium valproate
Number of subjects: 51
Study 16901421 — intervention group
Group type: COMPARATOR
Intervention: Control group (80 healthy children)
Number of subjects: 51
Study 15043351 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal orthosis for 6 months
Number of subjects: 0
Study 11318769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 : 80 000
Number of subjects: 195
Study 11318769 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2%
Number of subjects: 195
Study 11318769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 : 160 000
Number of subjects: 195
Study 9863095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo leave concentrated oral liquor (GLC)
Number of subjects: 0
Study 9863095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7934188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 177
Study 7934188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 2450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urovison
Number of subjects: 200
Study 2450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamiro
Number of subjects: 200
Study 2450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 200
Study 2450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urovison, Hexabrix, Iopamiro
Number of subjects: 200
Study 2450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast media
Number of subjects: 200
Study 31754962 — intervention group
Group type: EXPERIMENTAL
Intervention: AA + P + ADT
Number of subjects: 112
Study 31754962 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ADT
Number of subjects: 112